Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07038005
PHASE1
A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors
Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
View on ClinicalTrials.gov
Summary
This study includes two cohorts, respectively evaluating safety, tolerability and preliminary efficacy of intravenous and subcutaneous administration of SPGL008.
Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SPGL008 Monotherapy for Patients With Advanced Malignant Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
96
Start Date
2025-07-30
Completion Date
2027-06-08
Last Updated
2026-02-09
Healthy Volunteers
No
Conditions
Interventions
DRUG
SPGL008
Biological product
Locations (1)
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China